GSK plc (LON:GSK) Insider Jonathan Symonds Acquires 1,500 Shares

GSK plc (LON:GSK) insider Jonathan Symonds bought 1,500 shares of the business’s stock in a transaction that occurred on Friday, December 20th. The stock was purchased at an average price of GBX 1,315 ($16.49) per share, with a total value of £19,725 ($24,739.75).

Jonathan Symonds also recently made the following trade(s):

• On Wednesday, October 30th, Jonathan Symonds purchased 7,150 shares of GSK stock. The shares were acquired at an average price of GBX 1,394 ($17.48) per share, for a total transaction of £99,671 ($125,010.66).

GSK Price Performance

Shares of GSK stock opened at GBX 1,341.50 ($16.83) on Thursday. GSK plc has a 1-year low of GBX 1,282.50 ($16.09) and a 1-year high of GBX 1,823.50 ($22.87). The firm’s 50-day moving average price is GBX 1,382.54 and its two-hundred day moving average price is GBX 1,503.06. The company has a current ratio of 0.82, a quick ratio of 0.73 and a debt-to-equity ratio of 123.04. The stock has a market capitalization of £54.73 billion, a price-to-earnings ratio of 1,187.17, a P/E/G ratio of 1.24 and a beta of 0.31.

GSK Dividend Announcement

The firm also recently declared a dividend, which will be paid on Thursday, January 9th. Investors of record on Thursday, November 14th will be issued a dividend of GBX 15 ($0.19) per share. The ex-dividend date of this dividend is Thursday, November 14th. This represents a yield of 1.03%. GSK’s dividend payout ratio is 5,309.73%.

Analyst Upgrades and Downgrades

A number of equities analysts have recently commented on GSK shares. JPMorgan Chase & Co. reaffirmed an “underweight” rating on shares of GSK in a report on Wednesday, December 11th. Shore Capital restated a “buy” rating on shares of GSK in a research note on Wednesday, August 28th. Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a GBX 1,850 ($23.20) price objective on shares of GSK in a research note on Tuesday, September 3rd. Finally, Berenberg Bank cut their target price on GSK from GBX 1,820 ($22.83) to GBX 1,600 ($20.07) and set a “buy” rating for the company in a research report on Friday, November 29th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of GBX 1,805.83 ($22.65).

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.